www.fdanews.com/articles/69669-avanir-acquires-additional-rights-to-irisys-neurodex-technology
AVANIR Acquires Additional Rights to IriSys' Neurodex Technology
March 9, 2005
AVANIR Pharmaceuticals has announced that, through a wholly owned subsidiary, it has acquired from IriSys, additional rights to Neurodex, AVANIR's late-stage drug candidate for the treatment of multiple central nervous system disorders, which was sublicensed from IriSys in 2000. As a result, AVANIR, through its subsidiary, holds the exclusive worldwide marketing rights to Neurodex for five indications under a royalty-bearing license with the owner of the underlying technology, The Center for Neurologic Study.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19319320&full=1)